1. Home
  2. IRWD vs OOMA Comparison

IRWD vs OOMA Comparison

Compare IRWD & OOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.47

Market Cap

586.6M

Sector

Health Care

ML Signal

HOLD

Logo Ooma Inc.

OOMA

Ooma Inc.

HOLD

Current Price

$19.72

Market Cap

548.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRWD
OOMA
Founded
1998
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
586.6M
548.1M
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
IRWD
OOMA
Price
$3.47
$19.72
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$6.10
★ $26.80
AVG Volume (30 Days)
★ 1.6M
331.4K
Earning Date
11-09-2026
12-07-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1400.00
188.46
EPS
★ 0.55
0.20
Revenue
★ $298,276,000.00
$114,490,000.00
Revenue This Year
$59.19
$21.68
Revenue Next Year
$4.80
$4.82
P/E Ratio
★ $6.46
$98.70
Revenue Growth
8.88
★ 9.53
52 Week Low
$1.47
$9.79
52 Week High
$5.78
$26.19

Technical Indicators

Market Signals
Indicator
IRWD
OOMA
Relative Strength Index (RSI) 37.03 38.22
Support Level $3.04 $19.62
Resistance Level $3.96 $20.99
Average True Range (ATR) 0.18 0.65
MACD -0.01 -0.01
Stochastic Oscillator 11.97 20.00

Price Performance

Historical Comparison
IRWD
OOMA

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.

Share on Social Networks: